Predicting tumor outcome following cancer vaccination by monitoring quantitative and qualitative CD8+ T cell parameters

Journal of Immunology

Volumn 176, Issue 3, 2006, Pages 1999-2006

  Rosato, Antonio ^a   Zoso, Alessia ^a,c   Dalla Santa, Silvia ^a   Milan, Gabriella ^a   Del Bianco, Paola ^b   De Salvo, Gian Luca ^b   Zanovello, Paola ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; DNA VACCINE; P1A ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL SPECIFICITY; CONTROLLED STUDY; CYTOLYSIS; DRUG EFFICACY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; IMMUNOLOGICAL MONITORING; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MULTIVARIATE ANALYSIS; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROVOCATION TEST; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; SPLEEN CELL; SPLENECTOMY; T LYMPHOCYTE ACTIVATION; TUMOR; TUMOR GROWTH; TUMOR REGRESSION;

EID: 31144465972     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.176.3.1999     Document Type: Article

References (46)

1. Mocellin, S., S. Mandruzzato, V. Bronte, M. Lise, and D. Nitti. 2004. Part 1: vaccines for solid tumours. Lancet Oncol. 5: 681-689.
2. Mocellin, S., G. Semenzato, S. Mandruzzato, and C. Riccardo Rossi. 2004. Part II: vaccines for haematological malignant disorders. Lancet Oncol. 5: 727-737.
3. Nencioni, A., F. Gruenbach, F. Patrone, and P. Brossait. 2004. Anticancer vaccination strategies. Ann. Oncol. 15(Suppl. 4): iv153-iv160.
4. Rosenberg, S. A., J. C. Yang, and N. P. Restifo. 2004. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10: 909-915.
5. Coulie, P. G., and P. van der Bruggen. 2003. T-cell responses of vaccinated cancer patients. Curr. Opin. Immunol. 15: 131-137.
6. Keilholz, U., J. Weber, J. H. Finke, D. I. Gabrilovich, W. M. Kast, M. L. Disis, J. M. Kirkwood, C. Scheibenbogen, J. Schlom, V. C. Maino, et al. 2002. Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J. Immunother. 25: 97-138.
7. Shankar, G. 2002. Immune monitoring: it's prudent to adopt current quality regulations. Trends Biotechnol. 20: 495-497.
8. Brichard, V. G., G. Warmer, A. Van Pel, G. Morlighem, S. Lucas, and T. Boon. 1995. Individual differences in the orientation of the cytolytic T cell response against mouse tumor P815. Eur. J. Immunol. 25: 664-671.
9. Rosato, A., A. Zambon, G. Milan, V. Ciminale, D. M. D'Agostino, B. Macino, P. Zanovello, and D. Collavo. 1997. CTL response and protection against P815 tumor challenge in mice immunized with DNA expressing the tumor-specific antigen P815A. Hum. Gene Ther. 8: 1451-1458.
10. Bousso, P., A. Casrouge, J. D. Altman, M. Haury, J. Kanellopoulos, J. P. Abastado, and P. Kourilsky. 1998. Individual variations in the murine T cell response to a specific peptide reflect variability in naive repertoires. Immunity 9: 169-178.
11. Rosato, A., A. Zoso, G. Milan, B. Macino, S. Dalla Santa, V. Tosello, E. Di Carlo, P. Musiani, R. G. Whalen, and P. Zanovello. 2003. Individual analysis of mice vaccinated against a weakly immunogenic self tumor-specific antigen reveals a correlation between CD8 T cell response and antitumor efficacy. J. Immunol. 171: 5172-5179.
12. Jager, E., D. Jager, and A. Knuth. 2002. Clinical cancer vaccine trials. Curr. Opin. Immunol. 14: 178-182.
13. Anichini, A., C. Vegetti, and R. Mortarini. 2004. The paradox of T-cell-mediated antitumor immunity in spite of poor clinical outcome in human melanoma. Cancer Immunol. Immunother. 53: 855-864.
14. Romero, P., J. C. Cerottini, and D. E. Speiser. 2004. Monitoring tumor antigen specific T-cell responses in cancer patients and phase I clinical trials of peptide-based vaccination. Cancer Immunol. Immunother. 53: 249-255.
15. Rosato, A., S. Dalla Santa, A. Zoso, S. Giacomelli, G. Milan, B. Macino, V. Tosello, P. Dellabona, P. L. Lollini, C. De Giovanni, and P. Zanovello. 2003. The cytotoxic T-lymphocyte response against a poorly immunogenic mammary adenocarcinoma is focused on a single immunodominant class 1 epitope derived from the gp70 Env product of an endogenous retrovirus. Cancer Res. 63: 2158-2163.
16. Rosato, A., G. Milan, D. Collavo, and P. Zanovello. 1999. DNA-based vaccination against tumors expressing the P1A antigen. Methods 19: 187-190.
17. Bryant, J., R. Day, T. L. Whiteside, and R. B. Herberman. 1992. Calculation of lytic units for the expression of cell-mediated cytotoxicity. J. Immunol. Methods 146: 91-103.
18. 1998. United Kingdom Co-ordinating Committee on Cancer Research (UKC-CCR) guidelines for the welfare of animals in experimental neoplasia (second edition). Br. J. Cancer 77: 1-10.
19. Swets, J. A. 1988. Measuring the accuracy of diagnostic systems. Science 240: 1285-1293.
20. Scheibenbogen, C., P. Romero, L. Rivoltini, W. Herr, A. Schmittel, J. C. Cerottini, T. Woelfel, A. M. Eggermont, and U. Keilholz. 2000. Quantitation of antigen-reactive T cells in peripheral blood by IFNγ-ELISPOT assay and chromium-release assay: a four-centre comparative trial. J. Immunol. Methods 244: 81-89.
21. Edwards, K. M. 2001. Development, acceptance, and use of immunologic correlates of protection in monitoring the effectiveness of combination vaccines. Clin. Infect. Dis. 33(Suppl. 4): S274-S277.
22. Schatzkin, A., and M. Gail. 2002. The promise and peril of surrogate end points in cancer research. Nat. Rev. Cancer 2: 19-27.
23. Lotze, M. T., and R. C. Rees. 2004. Identifying biomarkers and surrogates of tumors (cancer biometrics): correlation with immunotherapies and immune cells. Cancer Immunol. Immunother. 53: 256-261.
24. + lymphocytes using class I peptide tetramers. Rev. Med. Virol 11: 11-22.
25. Klenerman, P., V. Cerundolo, and P. R. Dunbar. 2002. Tracking T cells with tetramers: new tales from new tools. Nat. Rev. Immunol. 2: 263-272.
26. Pantaleo, G., and R. A. Koup. 2004. Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know. Nat. Med. 10: 806-810.
27. Fong, L., Y. Hou, A. Rivas, C. Benike, A. Yuen, G. A. Fisher, M. M. Davis, and E. G. Engleman. 2001. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc. Natl. Acad. Sci. USA 98: 8809-8814.
28. Oka, Y., A. Tsuboi, T. Taguchi, T. Osaki, T. Kyo, H. Nakajima, O. A. Elisseeva, Y. Oji, M. Kawakami, K. Ikegame, et al. 2004. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc. Natl. Acad. Sci. USA 101: 13885-13890.
29. Bercovici, N., A. L. Givan, M. G. Waugh, J. L. Fisher, F. Vernel-Pauillac, M. S. Ernstoff, J. P. Abastado, and P. K. Wallace. 2003. Multiparameter precursor analysis of T-cell responses to antigen. J. Immunol. Methods 276: 5-17.
30. + T-cell responses. J. Clin. Oncol. 21: 1562-1573.
31. Whiteside, T. L., Y. Zhao, T. Tsukishiro, E. M. Elder, W. Gooding, and J. Baar. 2003. Enzyme-linked immunospot, cytokine flow cytometry, and tetramers in the detection of T-cell responses to a dendritic cell-based multipeptide vaccine in patients with melanoma. Clin. Cancer Res. 9: 641-649.
32. Belli, F., A. Testori, L. Rivoltini, M. Maio, G. Andreola, M. R. Sertoli, G. Gallino, A. Piris, A. Cattelan, I. Lazzari, et al. 2002. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J. Clin. Oncol 20: 4169-4180.
33. Butterfield, L. H., A. Ribas, V. B. Dissette, S. N. Amarnani, H. T. Vu, D. Oseguera, H. J. Wang, R. M. Elashoff, W. H. McBride, B. Mukherji, et al. 2003. Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin. Cancer Res. 9: 998-1008.
34. Rivoltini, L., C. Castelli, M. Carrabba, V. Mazzaferro, L. Pilla, V. Huber, J. Coppa, G. Gallino, C. Scheibenbogen, P. Squarcina, et al. 2003. Human tumor-derived heat shock protein 96 mediates in vitro activation and in vivo expansion of melanoma- and colon carcinoma-specific T cells. J. Immunol. 171: 3467-3474.
35. Gabrielsson, S., V. Brichard, O. Dhellin, T. Dorval, and C. Bonnerot. 2004. IFN-γ responses in peptide-treated melanoma patients measured by an ELISPOT assay using allogeneic dendritic cells. Anticancer Res. 24: 171-177.
36. Hirschowitz, E. A., T. Foody, R. Kryscio, L. Dickson, J. Sturgill, and J. Yannelli. 2004. Autologous dendritic cell vaccines for non-small-cell lung cancer. J. Clin. Oncol. 22: 2808-2815.
37. Lienard, D., D. Rimoldi, M. Marchand, P. Y. Dietrich, N. van Baren, C. Geldhof, P. Batard, P. Guillaume, M. Ayyoub, M. J. Pittet, et al. 2004. Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA. Cancer Immun. 4: 4.
38. Slingluff, C. L., Jr., G. R. Petroni, G. V. Yamshchikov, S. Hibbitts, W. W. Grosh, K. A. Chianese-Bullock, E. A. Bissonette, D. L. Barnd, D. H. Deacon, J. W. Patterson, et al. 2004. Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule. J. Clin. Oncol. 22: 4474-4485.
39. Svane, I. M., A. E. Pedersen, H. E. Johnsen, D. Nielsen, C. Kamby, E. Gaarsdal, K. Nikolajsen, S. Buus, and M. H. Claesson. 2004. Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase 1 study. Cancer Immunol. Immunother. 53: 633-641.
40. Mazzaferro, V., J. Coppa, M. G. Carrabba, L. Rivoltini, M. Schiavo, E. Regalia, L. Mariani, T. Camerini, A. Marchiano, S. Andreola, et al. 2003. Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer. Clin. Cancer Res. 9: 3235-3245.
41. Peterson, A. C., H. Harlin, and T. F. Gajewski. 2003. Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma. J. Clin. Oncol. 21: 2342-2348.
42. Lonchay, C., P. van der Bruggen, T. Connerotte, T. Hanagiri, P. Coulie, D. Colau, S. Lucas, A. Van Pel, K. Thielemans, N. van Baren, and T. Boon. 2004. Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen. Proc. Natl. Acad. Sci. USA 101(Suppl. 2): 14631-14638.
43. Van Baren, N., M.-C. Bonnet, B. Dréno, A. Khammari, T. Dorval, S. Piperno-Neumann, D. Liénard, D. Speiser, M. Marchand, V. G. Brichard, et al. 2005. Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. J. Clin. Oncol. 23: 9008-9021.
44. Perez-Diez, A., P. J. Spiess, N. P. Restifo, P. Matzinger, and F. M. Marincola. 2002. Intensity of the vaccine-elicited immune response determines tumor clearance. J. Immunol. 168: 338-347.
45. Blankenstein, T., and Z. Qin. 2003. The role of IFN-γ in tumor transplantation immunity and inhibition of chemical carcinogenesis. Curr. Opin. Immunol. 15: 148-154.
46. Coulie, P. G., and T. Connerotte. 2005. Human tumor-specific T lymphocytes: does function matter more than number? Curr. Opin. Immunol. 17: 320-325.